Rajendra Institute of Medical Sciences, Ranchi, Garhwa.
J Assoc Physicians India. 2022 Apr;70(4):11-12.
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. Therapeutic interventions at earlier stages can prevent or ameliorate most of the complications of decreased kidney function, as well as slow the progression to kidney failure. Coronary artery disease (CAD) is the most common cause of death in CKD patients. Low serum folic acid, low serum vitamin B12 and high serum homocysteine are commonly associated with CKD.
This work was a single-centre, cross-sectional, descriptive study which included 100 patients who met the criteria for CKD, as per KDIGO guidelines. Serum vitamin B12, serum folic acid, serum homocysteine and eGFR for each patient was measured and their association with the renal function and mortality outcome was noted.
A total of 100 patients (M:F=68:32) of chronic kidney disease were analyzed. Mean age of the study population was 51.55±16.23 years. On applying Pearson correlation between S. folic acid and eGFR, a linear correlation was found (p=0.001, correlation= 0.331). Similarly, an inverse correlation between S. homocysteine and eGFR (p<0.001, correlation=-0.573) was established. 15% patients died during the course of study. The mean folic acid among patients who died and patients who survived was 3.99±4.04ng/ml and 10.72±7.58ng/ml, respectively. The difference was statistically significant. The mean eGFR among those who died (mean=4.04±3.22ml/mint/1.73m2) was significantly lower (p<0.001) than the patients who survived during the study (mean=.16.22±12.66 ml/ mint/1.73m2).
Higher levels of homocysteine were more common in CKD patients as the disease progressed. It was also associated with poorer outcome (i.e. mortality risk). Advanced CKD staging was associated with increased mortality and lower folate levels. However, no association between serum vitamin B12 and renal/mortality outcome could be established in this study.
慢性肾脏病(CKD)定义为肾脏结构或功能异常,持续时间超过 3 个月,对健康有影响。在早期阶段进行治疗干预可以预防或改善大多数肾功能下降的并发症,并减缓向肾衰竭的进展。冠状动脉疾病(CAD)是 CKD 患者最常见的死亡原因。低血清叶酸、低血清维生素 B12 和高血清同型半胱氨酸通常与 CKD 相关。
本研究为单中心、横断面、描述性研究,纳入了符合 KDIGO 指南的 100 名 CKD 患者。测量了每位患者的血清维生素 B12、血清叶酸、血清同型半胱氨酸和 eGFR,并注意它们与肾功能和死亡率结果的关系。
共分析了 100 名(M:F=68:32)慢性肾脏病患者。研究人群的平均年龄为 51.55±16.23 岁。在应用 Pearson 相关分析 S.叶酸与 eGFR 之间的关系时,发现存在线性相关性(p=0.001,相关性=0.331)。同样,S.同型半胱氨酸与 eGFR 之间也存在负相关(p<0.001,相关性=-0.573)。在研究过程中,有 15%的患者死亡。死亡患者和存活患者的平均叶酸水平分别为 3.99±4.04ng/ml 和 10.72±7.58ng/ml,差异有统计学意义。死亡患者的平均 eGFR(平均=4.04±3.22ml/mint/1.73m2)明显低于研究期间存活患者(平均=16.22±12.66ml/mint/1.73m2)(p<0.001)。
随着疾病的进展,CKD 患者的同型半胱氨酸水平升高更为常见。它也与较差的预后(即死亡率风险)相关。晚期 CKD 分期与死亡率增加和叶酸水平降低相关。然而,在本研究中未能建立血清维生素 B12 与肾脏/死亡率结果之间的关系。